首页 > 市场调查报告书 > 医疗设备

医学影像诊断药物递输设备电子医疗设备内视镜检查设备

市场调查报告书

商品编码

1542887

全球心理健康数位药丸市场 - 2024-2031

Global Digital Pills for Mental Health Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球心理健康数位药丸市场规模达到2.735亿美元，预计2031年将达到4.201亿美元，2024-2031年预测期间复合年增长率为5.6%。

数位药丸是一种革命性的精神保健方法，它将技术和药理学相结合，提供个人化治疗。这些可摄入的感测器嵌入传统药丸中，监测药物依从性和生理反应，为医疗保健提供者提供即时资料。

这种创新方法增强了治疗效果，提高了患者参与度，并为管理心理健康状况提供了宝贵的见解，标誌着在寻求更精确和适应性疗法方面向前迈出了重要一步。

市场动态：

驱动程式和限制

精神健康障碍盛行率上升

全球心理健康数位药丸市场是由心理健康疾病日益普及所推动的。精神健康疾病数量的增加预计将成为市场成长的重要因素。在美国等成熟市场经济体和世界范围内，精神健康障碍是导致残疾的几个主要原因，包括重度忧郁症、躁郁症、精神分裂症和强迫症。

例如，根据约翰霍普金斯大学的出版物，估计 18 岁及以上的美国人中约有 26% 以及四分之一的成年人患有可诊断的精神障碍。

此外，根据心理健康基金会的数据，2022-2023 年，平均有 37.1% 的女性和 29.9% 的男性表示高度焦虑。 2022 年 7 月至 9 月，59.4% 的比例处于低至极低水准。而 40.5% 的人经历「中度」或「高度」焦虑。

此外，根据世界卫生组织的数据，到 2022 年，精神分裂症影响着全世界约 2,400 万人，即每 300 人中就有 1 人受到精神分裂症的影响。这一比率相当于成年人中每 222 人中就有 1 人患有此病。因此，预计上述因素将在预测期内推动市场成长。

与数位药丸相关的挑战

取得数位平板电脑的监管许可可能很困难且耗时。由于公司必须进行大量临床试验来证明其产品的安全性和有效性，因此进入市场可能会被推迟。敏感的健康资料是透过数位药丸收集的，这引发了隐私和安全问题。对于患者和公司来说，违规可能会导致灾难性后果。因此，上述挑战可能会阻碍市场成长。

细分市场分析

全球心理健康数位药丸市场根据产品类型、应用、最终用户和地区进行细分。

带有嵌入式感测器的数位药丸预计将主导市场份额

具有嵌入式感测器的数位药丸是一项革命性的医疗保健创新，它将药物与先进技术相结合，以提高治疗效果和依从性。这些智慧药丸将有关药物摄取、身体反应和生理指标的资料传输到安全的数位平台，为个人化和及时的干预提供即时见解。

药物消耗时间由嵌入式感测器监控，即时提供依从性资料。当出现依从性问题时，医疗保健专业人员可以藉助这些资料采取措施。

如果患者可以选择获得有关其药物使用的回馈，他们就更有可能坚持他们推荐的治疗方案。根据每位患者独特的依从习惯和药物反应，这些资料可以实现量身定制的治疗修改。因此，上述因素预计将保持该细分市场的主导地位。

市场地域占有率

预计北美将在心理健康数位药丸市场份额中占据重要地位

由于先进的追踪技术和研发投资等因素，以及精神健康疾病增加的推动，北美预计将在整个预测期内占据总市场份额的主要部分。数位药丸的采用提高了治疗依从性，从而缩短了康復时间并进一步促进了该地区的市场成长。

例如，根据 2021 年国家精神疾病联盟的数据，2021 年约 7.6% 的美国成年人同时患有药物滥用障碍和精神疾病

数位健康技术的研发得到了企业家和投资公司的广泛支持，从而形成了健康的新型数位药丸产品系列。製药公司、技术企业、医疗保健提供者和研究组织之间的合作可以促进数位药丸的开发和实施。因此，上述因素预计将保持该地区在市场份额上的主导地位。

Digital pills are a revolutionary approach to mental health care, combining technology and pharmacology to offer personalized treatments. These ingestible sensors, embedded within traditional pills, monitor medication adherence and physiological responses, providing real-time data to healthcare providers.

This innovative approach enhances treatment outcomes, improves patient engagement, and offers valuable insights into managing mental health conditions, marking a significant step forward in the quest for more precise and adaptive therapies.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of mental health disorders

The global digital pills for mental health market is driven by the increasing prevalence of mental health disorders. The increasing number of mental health disorders is expected to be a significant factor for the market growth. Mental health disorders account for several of the top causes of disability in established market economies, such as the U.S., and worldwide, and include major depression, bipolar disorder, schizophrenia, and obsessive-compulsive disorder.

For instance, according to a Johns Hopkins University publication, it is estimated that about 26% of Americans ages 18 and older and about 1 in 4 adults suffer from a diagnosable mental disorder.

Additionally, according to the Mental Health Foundation, in 2022-2023, an average of 37.1% of women and 29.9% of men reported high levels of anxiety. From July to September 2022, 59.4% experienced low to very low levels. Whereas 40.5% of people experienced 'medium' or 'high' levels of anxiety.

Also, according to WHO in 2022, Schizophrenia affects approximately 24 million people or 1 in 300 people worldwide. This rate is equal to 1 in 222 people among adults. Thus, the above factors are expected to drive market growth during the forecast period.

Challenges associated with the digital pills

Regulatory clearance for digital tablets can be difficult and time-consuming to obtain. Market entry can get delayed as a result of the substantial clinical trials that companies must do to prove the safety and effectiveness of their products. Sensitive health data is collected via digital pills, which raises privacy and security issues. For both patients and companies, a breach could lead to disastrous consequences. Thus, the above challenges could hamper the market growth.

Market Segment Analysis

The global digital pills for mental health market is segmented based on product type, application, end-user, and region.

Digital pills with embedded sensors segment is expected to dominate the market share

Digital pills with embedded sensors are a revolutionary healthcare innovation that integrates medication with advanced technology to improve treatment efficacy and adherence. These smart pills transmit data about medication ingestion, body response, and physiological metrics to a secure digital platform, providing real-time insights for personalized and timely interventions.

Medication consumption timing is monitored by embedded sensors, which provide adherence data in real-time. Healthcare professionals can take measures when adherence issues arise with the aid of this data.

Patients can be more likely to stick to their recommended regimens if they have the option to obtain feedback regarding their medicine use. Depending on each patient's unique adherence habits and drug responses, the data enables tailored therapy modifications. Thus, the above factors are expected to hold the segment in the dominant position.

Market Geographical Share

North America is expected to hold a significant position in the digital pills for mental health market share

North America is estimated to hold a major portion of the total market share throughout the forecast period owing to factors like advanced tracking technologies and R&D investments, driven by the rise in mental health disorders. The adoption of digital pills improves treatment adherence, leading to faster recovery times and further market growth in the region.

For instance, according to the National Alliance on Mental Illness in 2021, it stated that about 7.6% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2021

Research and development for digital health technologies is extensively supported by entrepreneurs and investment companies, which results in a healthy pipeline of new digital pill products. The development and implementation of digital pills can be facilitated by collaboration among pharmaceutical corporations, technology businesses, healthcare providers, and research organizations. Thus, the above factors are expected to hold the region in the dominant position in the market share.

Market Segmentation

By Product Type

Digital Pills with Embedded Sensors

Digital Pills Ingestible Sensors

Others

By Application

Depression

Anxiety Disorders

Schizophrenia

Bipolar Disorder

Others

By End-User

Healthcare Providers

Pharmaceutical Companies

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Otsuka America Pharmaceutical, Inc., and Idorsia Pharmaceuticals Ltd among others.

Why Purchase the Report?

To visualize the global digital pills for mental health market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of digital pills for mental health market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global digital pills for mental health market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the prevalence of mental health disorders
- 4.1.2. Restraints
  - 4.1.2.1. Challenges associated with the digital pills
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Digital Pills with Embedded Sensors*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Digital Pills Ingestible Sensors
6.4. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Depression*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Anxiety Disorders
7.4. Schizophrenia
7.5. Bipolar Disorder
7.6. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Healthcare Providers*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Pharmaceutical Companies
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
  - 9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  - 9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.3.1. U.S.
  - 9.2.3.2. Canada
  - 9.2.3.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
  - 9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.4.1. Germany
  - 9.3.4.2. UK
  - 9.3.4.3. France
  - 9.3.4.4. Italy
  - 9.3.4.5. Spain
  - 9.3.4.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
  - 9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.4.1. Brazil
  - 9.4.4.2. Argentina
  - 9.4.4.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
  - 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.4.1. China
  - 9.5.4.2. India
  - 9.5.4.3. Japan
  - 9.5.4.4. South Korea
  - 9.5.4.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
  - 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Otsuka America Pharmaceutical, Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Idorsia Pharmaceuticals Ltd (*LIST NOT EXHAUSTIVE)